文献速递脑血管病

不明发病时间卒中静脉溶栓:SITS-ISTR登记研究结果

Intravenous Thrombolysis in Unknown-Onset Stroke: Results From the Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Registry.
PubMed 文献 · Stroke · 2017-02-07

基于SITS-ISTR登记2010-2014年47 237例接受静脉tPA的急性缺血性卒中患者,比较不明发病时间(UKO,n=502)与发病4.5小时内(n=44 875)治疗者的安全性和有效性。UKO组症状性颅内出血风险相似(aOR 1.09,95%CI 0.44-2.67),功能独立无显著差异(aOR 0.79,95%CI 0.56-1.10),但死亡率更高(aOR 1.58,95%CI 1.04-2.41)。

要点

  • UKO患者静脉溶栓后症状性颅内出血风险与4.5小时内治疗者相似
  • UKO患者死亡率显著高于4.5小时内治疗者(aOR 1.58)
  • UKO患者功能独立比例与4.5小时内治疗者无显著差异

核心结论

  • UKO卒中患者静脉阿替普酶治疗不增加症状性颅内出血风险,但死亡率增高且良好预后减少。

研究设计与样本

  • 分析SITS-ISTR登记2010-2014年47 237例接受静脉tPA的急性缺血性卒中患者。
  • UKO组502例,发病4.5小时内治疗组44 875例。

主要发现

  • UKO组年龄更大、基线卒中更重、door-to-needle时间更长。
  • 症状性颅内出血调整OR 1.09(95%CI 0.44-2.67)。
  • 功能独立(mRS 0-2)调整OR 0.79(95%CI 0.56-1.10)。
  • 死亡调整OR 1.58(95%CI 1.04-2.41)。
  • 4.5小时内组全mRS范围残疾减少(共同调整OR 1.29,95%CI 1.01-1.65)。

临床怎么用

  • UKO卒中静脉溶栓需权衡死亡率增高风险,个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Stroke patients with unknown onset (UKO) are excluded from thrombolytic therapy. We aim to study the safety and efficacy of intravenous alteplase in ischemic stroke patients with UKO of symptoms compared with those treated within 4.5 hours in a large cohort. METHODS: Data were analyzed from 47 237 patients with acute ischemic stroke receiving intravenous tissue-type plasminogen activator in hospitals participating in the Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Registry between 2010 and 2014. Two groups were defined: (1) patients with UKO (n=502) and (2) patients treated within 4.5 hours of stroke onset (n=44 875). Outcome measures were symptomatic intracerebral hemorrhage per Safe Implementation of Treatment in Stroke on the 22 to 36 hours post-treatment neuroimaging and mortality and functional outcome assessed by the modified Rankin Scale at 3 months. RESULTS: Patients in UKO group were significantly older, had more severe stroke at baseline, and longer door-to-needle times than patients in the ≤4.5 hours group. Logistic regression showed similar risk of symptomatic intracerebral hemorrhage (adjusted odds ratio, 1.09; 95% confidence interval, 0.44-2.67) and no significant differences in functional independency (modified Rankin Scale score of 0-2; adjusted odds ratio, 0.79; 95% confidence interval, 0.56-1.10), but higher mortality (adjusted odds ratio, 1.58; 95% confidence interval, 1.04-2.41) in the UKO group compared with the ≤4.5 hours group. Patients treated within 4.5 hours showed reduced disability over the entire range of modified Rankin Scale compared with the UKO group (common adjusted odds ratio, 1.29; 95% confidence interval, 1.01-1.65). CONCLUSIONS: Our data suggest no excess risk of symptomatic intracerebral hemorrhage but increased mortality and reduced favorable outcome in patients with UKO stroke compared with patients treated within the approved time window.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Dorado L, Ahmed N, Thomalla G, et al. Intravenous Thrombolysis in Unknown-Onset Stroke: Results From the Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Registry. Stroke. 2017. PMID: 28174326. doi:10.1161/STROKEAHA.116.014889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。